Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines

被引:31
作者
Lin, H
Nieda, M
Nicol, AJ
机构
[1] Queensland Inst Med Res, Canc Res Ctr, Brisbane, Qld 4029, Australia
[2] Univ Queensland, Dept Med, Brisbane, Qld 4000, Australia
[3] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan
关键词
NKT cells; cytokines; alpha-galactosylceramide; KRN7000;
D O I
10.1002/eji.200324834
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human Valpha24(+)Vbeta11(+) NKT (NKT) cells have immune regulatory activities associated with rejection of tumors, infections and control of autoimmune diseases. They can be stimulated to proliferate using alpha-galactosylceramide (KRN7000) and have the potential for therapeutic manipulation. Subpopulations of NKT cells (CD4(+)CD8(-), CD4(-)D8(+) and CD4(-)CD8(-)) have functionally distinctive Th1/Th2 cytokine profiles and their relative numbers following stimulation may influence the Th1/Th2 balance, which may result in or prevent disease. We aimed to determine the effect of different cytokines in culture during stimulation of NKT cells on the relative proportions of NKT cell subpopulations. Our results show that all NKT cell subpopulations expanded following stimulation with KRN7000 and IL-2, IL-7, IL-1 2 or IL-15. Expansion capacity differed between subpopulations, resulting in different relative proportions of CD4(+) and CD4(-) NKT cell subpopulations, and this was influenced by the cytokine used for stimulation. A Th1-biased environment was observed after stimulation of NKT cells. NKT cells expanded under all conditions evaluated demonstrated significant cytotoxicity against U937 tumor cells. In view of the potential for NKT cell subsets to alter the balance of Th1 and Th2 environment, these data provide insights into the effects of NKT cell manipulation for possible therapeutic applications in different disease settings.
引用
收藏
页码:2664 / 2671
页数:8
相关论文
共 38 条
[1]   CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution [J].
Brossay, L ;
Chioda, M ;
Burdin, N ;
Koezuka, Y ;
Casorati, G ;
Dellabona, P ;
Kronenberg, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (08) :1521-1528
[2]  
Carnaud C, 1999, J IMMUNOL, V163, P4647
[3]  
Eberl G, 2000, EUR J IMMUNOL, V30, P985, DOI 10.1002/(SICI)1521-4141(200004)30:4<985::AID-IMMU985>3.0.CO
[4]  
2-E
[5]   Requirements for CD1d recognition by human invariant V alpha 24(+) CD4(-)CD8(-) T cells [J].
Exley, M ;
Garcia, J ;
Balk, SP ;
Porcelli, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (01) :109-120
[6]   An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity [J].
Fischer, K ;
Andreesen, R ;
Mackensen, A .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 259 (1-2) :159-169
[7]   Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining [J].
Gumperz, JE ;
Miyake, S ;
Yamamura, T ;
Brenner, MB .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (05) :625-636
[8]   Killing activity of human umbilical cord blood-derived TCRValpha24+ NKT cells against normal and malignant hematological cells in vitro:: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells [J].
Hagihara, M ;
Gansuvd, B ;
Ueda, Y ;
Tsuchiya, T ;
Masui, A ;
Tazume, K ;
Inoue, H ;
Kato, S ;
Hotta, T .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (01) :1-8
[9]   The roles of IFNγ in protection against tumor development and cancer immunoediting [J].
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :95-109
[10]   Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells [J].
Kadowaki, N ;
Antonenko, S ;
Ho, S ;
Rissoan, MC ;
Soumelis, V ;
Porcelli, SA ;
Lanier, LL ;
Liu, YJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (10) :1221-1226